Ocular Therapeutix (OCUL) Tops Q3 EPS by 2c

Ocular Therapeutix (NASDAQ: OCUL) reported Q3 EPS of ($0.45), $0.02 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $829 thousand versus the consensus estimate of $580 thousand.

“We have had very productive quarter,” said Antony Mattessich, President and Chief Executive Officer. “As we had hoped, the first phase of our DEXTENZA launch has given us the confidence to expand our field presence by 50%. Now, with a good understanding of the time and effort it takes to remove the obstacles at the ambulatory surgical centers and Hospital Outpatient Departments, and a J-code in place as of October 1st, we are set to capitalize on our expanded reach. Additionally, we have recently restructured operations in a way that allows us to complete key clinical programs while extending our runway. Overall we are in great shape to deliver in the future.”

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
• Inhibikase Therapeutics (IKT) Issues Letter to Shareholders and Provides Update on Development Programs
• Glacier Bancorp (GBCI) Misses Q1 EPS by 3c